Chemistry Reference
In-Depth Information
[28]
Taft CA, da Silva VB, de Andrade P, Kawano DF, Morais PAB, Almeida JR, Carvalho I,
Taft CA and Silva CHTP.
In silico
design and search for acetylcholinesterase inhibitors in
Alzheimer's disease with a suitable pharmacokinetic profile and low toxicity, Future
Medicinal Chemistry, 2011, 3: 947- 960.
[29]
da Silva VB, Leopoldino AM, Silva CHTP, Taft CA, Toxicophoric and Metabolic
In Silico
Evaluation of Benzimidazole and Phenylbenzamide Derivatives with Potential Application
as Anticancer Agents. Drug Metabolism Letters, 2011, 5:267- 275.
[30]
Taft CA and Silva CHTP. An Overview of Tropical Parasitic Diseases: Causative Agents,
Targets and Drugs. In Chemoinformatics: Directions Toward Combating Neglected
Diseases. Bentham Sci. Pub. (Dubai, U.A.E.) Eds. T. C. Ramalho, M. P. Freitas and E. F.
F. da Cunha. 2012. Pp. 174-196.
[31]
Taft CA. Silva CHTP, Silva CHTP, Comments on the paper Levinthals question, revisited,
and answered, Journal of Biomolecular Structure & Dynamics. 2013,13:1001-1002.
[32]
Hage-Melim L, Sampaio S, Taft CA, Silva CHTP, Phospholipase A2 Inhibitors Isolated
From Medicinal Plants: Alternative Treatment Against Snakebites. Mini-Reviews in
Medical Chemistry, 2013, 13: 1348-1356.
[33]
Pinsetta FR, Taft CA, Silva CHTP, Rational Design of Novel Potential p38α MAPK
Inhibitors with Drug-like Properties using pharmacophore and Similarity-based Virtual
Screening Procedures. Current Bioactive Compounds. 2013, 13: 3-13.
[34]
Semighini EP, Taft CA, Silva CHTP, Structure and Ligand Based Rational Drug Design for
Bace-1 Inhibitors. Current Bioactive Compounds, 2013, 9: 14-20.
[35]
Almeida JR, Taft CA, Silva CHTP. Density Functional Theory, Molecular Interaction
Fields, Pharmacophore, Virtual Screening and Physical Chemistry of the Interactions of
Novel Acetylcholinesterase Inhibitors in Alzheimer´s Disease. Current Physical Chemistry.
2013, 3: 419-430.
[36]
Susimaire Pedersoli-Mantoani, Vinicius Barreto da Silva, Carlton Anthony Taft and Carlos
Henrique Tomich de Paula da Silva.
Pharmacophore-based Design of Novel Potential Tau
Ligands for Alzheimer's Disease Treatment, Current Physical Chemistry, 2014, 4:35-44.
[37]
Ferreira FP, Couto WF, Fontana F, Taft CA, da Silva CHTP. Molecular Dynamics, Density
Functional Theory, Pharmacophore Modeling, Molecular Interaction Fields,
Pharmacodynamic, Pharmacokinetic Toxicity Investigation of Novel Bioactive Compounds
Interacting with CDK2 Surfaces. Current Physical Chemistry, 2014, 4:94-105.
[38]
Paul SM, Mytelka DS, Dunwiddlie CT, Persinger CC, Munon BH, Lindorbg SR, Schacht
AL How to improve R&D roducivity; the pharmaceutical industry's grand challenge. Nat
Rev Drug Discov. 2010, 9:203-214.
[39]
Stouch TR, The errors of our ways: taking account of error in computer-aided drug design
to build confidence intervals for our next 25 years, J. Comput. Aided Mol. Des. 2012,
26:125-134.
[40]
Dongyue C, Junmei W, Rui Z, Youyong L, Huidong Y and Tingjun H. Evaluation in Drug
Discovery. PharmacoKinetics Knowledge Base (PKKB):A Comprehensive Database of
Pharmacokinetic and Toxic Properties for Drugs, J. Chem. Inf. Model., 2012, 52: 1132-
1134
[41]
Greer J, Erickson JW, Baldwin JJ, Varney MD, Application of the three-dimensional
structures of protein target molecules in structure-based drug design. J. Med. Chem. 1994,
37:1035-1054.
